Premium
P2‐161: Novel AB Oligomer–Specific Antibodies and Stabilized AB Oligomers as Reliable and Disease Relevant Reference Standards in Alzheimer’s Biomarker Assays
Author(s) -
Tepper Armand W.J.W.,
Diggelen Femke,
Poli Angela,
Scheefhals Guus A.P.H.,
Vis Joost D.J.,
Hoogveld Emily,
Schut Ivar C.,
Anderegg Birgit,
Boer Marco
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1328
Subject(s) - oligomer , biomarker , chemistry , monomer , disease , antibody , computational biology , amyloid (mycology) , biochemistry , biology , medicine , immunology , pathology , polymer , organic chemistry , inorganic chemistry
associated with cognitive impairment. Several studies demonstrated that mild cognitive impairment (MCI) in MetS subjects has been positively associated with hyperglycemia, hyperinsulinemia and dyslipidemia. However, a prognostic biomarker for the development of MCI in patients with MetS has not been thoroughly investigated. Much evidence showed that systemic inflammation has been known to be responsible for several pathological conditions, including diabetes, cardiovascular diseases and neurodegeneration. Recently, the neutrophil-lymphocyte ratio (NLR), an indicator for the systemic inflammation, has been used as a predicted biomarker for the development of several types of cancers (lung cancer, gastro-intestinal tracts cancer) and cardiovascular diseases. Nevertheless, the association of NLR and levels of cognitive decline in patients withMetS has not been investigated. The present study hypothesized that NLR is associated with the occurrence of MCI in patients with MetS. Methods: One-hundred and seventy MetS patients were enrolled in the present study. Average age of all patients was 6062 years old. MetS was defined by insulin-resistant state (impaired fasting glucose) in complication with dyslipidemia and high level of body mass index (BMI). Metabolic parameters including plasma glucose, plasma lipid profiles and the complete blood count (CBC) were collected. NLR level was calculated by the ratio of neutrophil to lymphocyte level derived from CBC measurement. We compared the effect of an individual MetS components and NLR level on changes in cognitive status by using the Montreal Cognitive Assessement (MoCA) test. Results: The prevalence of MCI, characterized by a MoCA score less than 26, in MetS patients was 94% (Fig. 1A). A negative correlation between HbA1Clevels and MoCA score was found in MetS patients (r1⁄4-0.152, p<0.05, Fig 1B). Interestingly, we found that MoCA score was significantly showed the negative correlation with NLR (r1⁄4 -0.245, p<0.01, Fig. 1C). However, other MetS factors, including fasting blood glucose level, lipid profiles, body mass index and waist circumference, did not significantly predict cognitive performance. Conclusions:These findings suggest that poor glycemic control, by measuring HbA1C, and NLR levels predicted poorer cognitive performance outcomes in MetS patients.